<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345370</url>
  </required_header>
  <id_info>
    <org_study_id>ECOM-Glioblastome</org_study_id>
    <nct_id>NCT01345370</nct_id>
  </id_info>
  <brief_title>Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients</brief_title>
  <acronym>ECOM</acronym>
  <official_title>Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for newly diagnosed glioblastomas currently involves surgical resection followed by&#xD;
      Temozolomide chemotherapy with concomitant radiotherapy, and then 6 cycles of Temozolomide in&#xD;
      adjuvant. According to many studies, only those patients not expressing the enzyme repair&#xD;
      MGMT benefit from the adjunction of Temozolomide. Therefore, many patients receive&#xD;
      unnecessary treatment. The aim of this project is to compare different techniques for&#xD;
      analysis of MGMT in order to choose the approach with the best cost/utility ratio, which will&#xD;
      allow the selection of patients likely to respond to TMZ chemotherapy during the first course&#xD;
      of GBM treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment for newly diagnosed glioblastomas (GBM) currently involves surgical resection&#xD;
      followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles&#xD;
      of TMZ in adjuvant (Stupp schedule). According to many studies, only those patients not&#xD;
      expressing the enzyme repair MGMT benefit from the adjunction of TMZ. Therefore, many&#xD;
      patients receive unnecessary treatment at an average cost of about 15,000 euros.&#xD;
&#xD;
      The aim of this project is to compare different techniques for analysis of MGMT in order to&#xD;
      choose the approach with the best cost/utility ratio, which will allow the selection of&#xD;
      patients likely to respond to TMZ chemotherapy during the first course of GBM treatment.&#xD;
      Another aspect of this project is to evaluate the extra cost produced by TMZ treatment, and&#xD;
      therefore the expected cost saving in the case of using a reliable predictive factor. This&#xD;
      kind of evaluation is of great importance, as the MGMT test status is beginning to appear in&#xD;
      the decisional care trees of high-grade gliomas The two main techniques for MGMT analysis are&#xD;
      currently immunohistochemistry (IH) and molecular analysis of promoter methylation of the&#xD;
      gene. Immunohistochemistry is simple and quick, but there is no consensus about labelling or&#xD;
      evaluation of the staining, all of which could lead to variability in results. Studies of&#xD;
      promoter methylation are currently performed by the MS-PCR technique, in particular the&#xD;
      article published in the N Engl J Med in 2005 showing that only patients with a methylated&#xD;
      promoter benefit from TMZ adjunction. This technique appears somewhat rudimentary compared to&#xD;
      techniques avoiding subjectivity linked to eye reading of the gel after electrophoresis of&#xD;
      PCR products.&#xD;
&#xD;
      In phase one of this multicenter national study, IH, MS-PCR, MethyLight, pyrosequencing and&#xD;
      MS-HRM will be compared in a retrospective study on 100 samples (frozen for molecular&#xD;
      analysis and paraffin-embedded for IH), taken from patients treated according to the Stupp&#xD;
      protocol and with a follow-up of 18 months at least. In phase 2, the two techniques with the&#xD;
      best cost/efficacy ratio (based on predictive value, analytical quality and feasibility of&#xD;
      the test) will be implemented in all the laboratories according to a standard protocol&#xD;
      developed by the referral centre for the tests. The dissemination of quality controls will&#xD;
      allow us to check that the same results are obtained from one laboratory to another. In phase&#xD;
      3, samples will be analysed prospectively in the different centres and a medico-economic&#xD;
      analysis will be undertaken on the integration of MGMT analysis into the standard care of GBM&#xD;
      patients. Two types of analysis will be performed: i) on the costs of the techniques,&#xD;
      allowing us in particular to estimate the possible additional clinical cost generated and its&#xD;
      effect on the cost of a hospital stay, in order to adjust the charging system, and ii) on&#xD;
      alternative care strategies for the patients, with or without screening, leading to improve&#xD;
      the target of treatments by TMZ, with the aim of improving the definition of &quot;options and&#xD;
      recommendations&quot; (cost-utility analysis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival of patients according to their MGMT status.</measure>
    <time_frame>12 months after last enrollment</time_frame>
    <description>Predictive MGMT methylation tests values related to mean overall survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Stupp protocole</arm_group_label>
    <description>All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>According to sites procedures</description>
    <arm_group_label>Stupp protocole</arm_group_label>
    <other_name>Temodal (brand name).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>According to sites procedures</description>
    <arm_group_label>Stupp protocole</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Freezed or/and parffine embedded tumor samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with glioblastoma, eligible to resection and to a treatment according to the Stupp&#xD;
        schedule.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult, age from 18 to 70&#xD;
&#xD;
          -  Pre-surgical diagnosis compatible with a primary or secondary sub-tentorial&#xD;
             glioblastoma than can be resected&#xD;
&#xD;
          -  No counter-indication to an adjuvant treatment according to the Stupp schedule&#xD;
&#xD;
          -  Free written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of tumor sample available&#xD;
&#xD;
          -  Definite histology not related to a glioblastoma or a main oligodendroglioma component&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Basse Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Salpetriere</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord Pas-de-Calais</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>Poitou-Charentes</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Rhone-Alpes</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.</citation>
    <PMID>15758010</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <name_title>Veronique QUILLIEN, MD</name_title>
    <organization>Center Eugene Marquis</organization>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

